Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

February 8, 2023

https://www.globenewswire.com/news-release/2023/02/08/2603834/0/en/Century-Therapeutics-Announces-First-Patient-Dosed-in-First-In-Human-Phase-1-ELiPSE-1-Trial-Evaluating-CNTY-101-in-Relapsed-or-Refractory-CD19-Positive-B-cell-Lymphomas.html

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch –

Read more at globenewswire.com

Related news for (IPSC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.